The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
AACR approaches, along with ASCO abstract titles.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.